Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-02
2007-10-02
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
11349373
ABSTRACT:
Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. Embodiments of these methods can diminish adverse side effects.
REFERENCES:
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4465458 (1984-08-01), Nishino et al.
patent: 4596807 (1986-06-01), Crosby
patent: 5068433 (1991-11-01), Melloni et al.
patent: 5192751 (1993-03-01), Thor
patent: 5281624 (1994-01-01), Gehlert et al.
patent: 5391735 (1995-02-01), Melloni et al.
patent: 5441985 (1995-08-01), Foreman
patent: 5744474 (1998-04-01), Thor
patent: 5922914 (1999-07-01), Gage et al.
patent: 5998430 (1999-12-01), Schwantes et al.
patent: 6028070 (2000-02-01), Heiligenstein
patent: 6046193 (2000-04-01), Heiligenstein
patent: 6066643 (2000-05-01), Perry
patent: 6290986 (2001-09-01), Murdock et al.
patent: 6479074 (2002-11-01), Murdock et al.
patent: 6572880 (2003-06-01), Murdock et al.
patent: 6610690 (2003-08-01), Wong et al.
patent: 6642235 (2003-11-01), Wong et al.
patent: 2002/0015713 (2002-02-01), Murdock et al.
patent: 2002/0061910 (2002-05-01), Wong et al.
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2003/0040464 (2003-02-01), Wong et al.
patent: 2014981 (1979-09-01), None
patent: 2167407 (1988-05-01), None
patent: WO96/12485 (1996-05-01), None
patent: WO97/35584 (1997-10-01), None
patent: WO97/35586 (1997-10-01), None
patent: WO99/11208 (1999-03-01), None
patent: WO99/15163 (1999-04-01), None
patent: WO99/15176 (1999-04-01), None
patent: WO99/15177 (1999-04-01), None
patent: WO99/20279 (1999-04-01), None
patent: WO99/52518 (1999-10-01), None
patent: WO99/52531 (1999-10-01), None
patent: WO99/58130 (1999-11-01), None
patent: WO 00/00120 (2000-01-01), None
patent: WO 01/26623 (2001-04-01), None
patent: WO 01/47503 (2001-07-01), None
patent: WO 01/62236 (2001-08-01), None
www.wrongdiagnosis.com/sym/fatigue (1-12) 2000.
J.J. Schildkraut, The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence, Am. J. of Psychiatry, vol. 122, pp. 509-522 (Nov. 1965).
T.H. Svensson, et al., Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: α-Receptor Mediation, Science, vol. 202, pp. 1089-1091 (1984).
E. Richelson et al., Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block Norepinephrine Uptake, Europ. J of Pharmacology, vol. 104, pp. 277-286 (1984).
C.B Nemeroff, The Neurobiology of Depression, Scientific American (1986) (8 pages).
M. Riva et al., Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies, J. Drug Dev., vol. 1, No. 4, pp. 243-253 (1989).
T. Pacholczyk et al., Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter, Nature, vol. 350, No. 28, pp. 350-356 (Mar. 1991).
M. Max et al., Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial, Pain, vol. 45, pp.3-9 (1991).
E. Richelson, Biological Basis of Depression and Therapeutic Relevance, J. Clin. Psychiatry, vol. 52, No. 6, Suppl., pp. 4-10 (Jun. 1991).
M. Max et al., Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy, New Engl. J. Med., vol. 326, No. 19, pp. 1250-1256 (1992).
B. Cusack et al., Binding of Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds, Pschopharmacology, vol. 114, pp. 559-565 (1994).
M. Max, Treatment of Post-Herpetic Neuralgia: Antidepressants, Ann. Neurol., vol. 35, Suppl., pp. S50-S53 (1994).
W. Reimann et al., Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol, Biochem. Pharmacol., vol. 47, No. 12, pp. 2289-2293 (1994).
Watson, Antidepressant Drugs as Adjuvant Analgesics, J. Pain and Symptom. Manage., vol. 9(6), pp. 392-405 (1994).
Justin, Basic Principles of Chronic Pain Management, Pain, pp. 255-267 (IASP Press, Seattle, 1996).
C. Pellizzoni et al., Pharmacokinetics of Reboxetine in Healthy Volunteers. Single Against Repeated Oral Doses and Lack of Enzymatic Alterations, Biopharm. Drug Dispos., vol. 17, No. 7, pp. 623-633 (1996).
R.J. Baldessarini, Depression and Mania, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Chapter 19, pp. 431-439, (1996).
B.E. Leonard, Noradrenaline in Basic Models of Depression, European Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S11-S16 (1997).
Discussion, European Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S71-S73 (1997).
S.A. Montgomery, Is There a Role For a Pure Noradrenergic Drug in the Treatment of Depression?, Eur. Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S3-S9 (1997).
S.A. Montgomery, Reboxetine: Additional Benefits to the Depressed Patient, J. Psychopharmacology (Oxf), 11:4 Abstract (1997).
I. Hindmarch, The Effects of Antidepressants on Psychomotor Function With Particular Reference to Reboxetine, Eur. Neuropsychopharmacology, vol. 7, Suppl. 1, pp. S17-S21 (1997).
E. Frigerio et al., Pharmacokinetics of Reboxetine Enantiomers in the Dog, Chirality, vol. 9, pp. 303-306 (1997).
A. Frazer, Pharmacology of Antidepressants, J. Clinical Psychopharmacology, vol. 17, No. 2, Suppl. 1, pp. 2S-18S (1997).
B.E. Leonard, The Role of Noradrenaline in Depression: A Review, J. Psychopharmacology, vol. II, No. 4, Suppl., pp. S39-S47 (1997).
Dostert et al., Review of the Pharmacokinetics and Metabolism of Reboxetine, a Selective Noradrenaline Reuptake Inhibitor, Euro. Neuropsychopharmacol., vol. 7, Suppl. 1, pp. S23-S35 (1997).
M. Owens et al., Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites, J. Pharmacol. Exp. Ther., vol. 283, pp. 1305-1322 (1997).
M. Mucci, Reboxetine: A Review of Antidepressant Tolerability, Journal of Psychopharmacology, Oxford University Press, 11(4):533-537 Supp, (1997).
D. Healy et al., The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?, J. of Affective Disorders, vol. 51, pp. 313-322 (1998).
Anonymous, Reboxetine—Another New Antidepressant, Drugs and Therapeutics Bull, 36 (11) (1998).
S.A. Montgomery, The Place of Reboxetine in Antidepressant Therapy, J. of Clinical Psychiatry, vol. 59, Suppl. 14, pp. 26-29 (1998).
G.D. Burrows et al., Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review, J. Clin. Psychiatry, vol. 59, Suppl. 14, 4 pages (1998).
J. Massana, Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability, J. Clin. Psychiatry, vol. 59, Suppl. 14, pp. 8-10 (1998).
A. Harkin et al., Activity and Onset of Action of Reboxetine and Effect of Combination With Sertraline in an Animal Model of Depression Eur. J. of Pharmacology, pp. 1-10 (1998).
Denolle et al., Hemodynamic Effects of Reboxetine in Healthy Male Volunteers, Clin. Pharm. Ther., vol. 66(3), pp. 282-287 (1999).
The Merck Manual, 17th ed., pp. 2480-83 (Merck & Co., Whitehouse Station, NJ, Apr. 1999).
J. Massana et al., Reboxetine: A Double-Blind Comparison With Fluoxetine in Major Depressive Disorder, Int. Clin. Psychopharmacol, vol. 14, No. 2, pp. 73-80 (1999).
J.C. Fleishaker et al., Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics, Biopharm. Drug Dispos. vol. 20, No. 1, pp. 53-57 (1999).
K. Moore et al., Tissue Distribution of Tramadol and Metabolites in an Overdose Fatality, Am. J. of Forensic Med. and Path., vol. 20, No. 1, pp. 98-100 (1999).
S. Kasper, From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy, International Clinical Psychopharmacology, vol. 14, Suppl. 1, pp. S27-S31 (May 1999).
J. Mark Ruscin and Nora E. Morgenstern, Tolterodine Use for Symptoms of Overactive Bladder, The Annals of Pharmacotherapy, Abstract vol. 33, pp. 1073-1082 (Oct. 1999).
B.E. Leonard and D. Healy, The Differential Effects of Antidepressants,
Ahmed Saeeduddin
Marshall Robert C.
McArthur Robert
Taylor Duncan P.
Wong Erik H. F.
Gembeh Shirley V.
Marschel Ardin H.
Pharmacia & Upjohn Company
LandOfFree
Method of treating chronic fatigue syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating chronic fatigue syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating chronic fatigue syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861977